Poland· PL-100411705
Imfinzi
A durvalumab product containing durvalumabum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Durvalumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF03 (durvalumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Durvalumab · ATC L01FF03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of durvalumab costs, country by country.
Normalised to the WHO defined daily dose (53.6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Durvalumab · price per daily dose (53.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$274.31
The record
At a glance
URPL (Poland)- Active substance
- Durvalumabum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- L01FF03
- ATC class
- Durvalumab
- Defined daily dose
- 53.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05000456031486
- gtin05000456031493
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for durvalumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Durvalumab · interactions on record
82 records
- 30 severe
- 45 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Durvalumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandImfinzi2care4 ApS
- CzechiaIMFINZIAstraZeneca AB, Södertälje
- BelgiumImfinzi 50 mg/mlAstraZeneca
- SwedenImfinzi 50 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- IrelandIMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB
- IcelandImfinziAstraZeneca AB
- NorwayImfinziAstraZeneca AB (2)
- United StatesIMFINZIAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imfinzi
- Liechtenstein · Imfinzi
- Norway · Imfinzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8e2894cd-7b6a-49fd-b3cd-d562c21873d0 GET /v1/drugs/8e2894cd-7b6a-49fd-b3cd-d562c21873d0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "50 mg/ml",
"packaging": "05000456031486 ¦ Rpz ¦ EU/1/18/1322/002 ¦ 130007\n1 fiol. 2,4 ml\n05000456031493 ¦ Rpz ¦ EU/1/18/1322/001 ¦ 130008\n1 fiol. 10 ml",
"substance": "Durvalumabum 50 mg/ml",
"common_name": "Durvalumabum",
"pl_product_id": "100411705",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about durvalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.